Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model
Clinical Transplantation · 2026-03 · 40 (3)
DOI: 10.1111/ctr.70488 ↗At a glance
Validierungsstudie in Clinical Transplantation, published online on 2026-02-25. Written by Hao Liu and 17 co-authors. Institution: J.C. Walter Jr. Transplant Center and Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Liver Transplantation, Carcinoma, Hepatocellular, Liver Neoplasms, Waiting Lists. 38 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Liver transplantation (LT) is the only curative option for patients with unrespectable hepatocellular carcinoma (HCC). In the United States. current organ allocation policies grant the same priority to patients with tumors within the Milan criteria. This uniform approach leads to higher waitlist dropout among candidated with more advanced tumors of with more aggressive tumor biology. A model to stratify HCC candidates into different risk groups could optimize organ allocation by providing priority to patients within transplantable criteria but at increased risk of dropout.
Methods
Data from 30,565 adult HCC LT candidates within the Scientific Registry of Transplant Recipients (SRTR) (2002–2022) were used. Inclusion criteria were age ≥18 years and tumors within Milan criteria. Recipients of previous transplants, multi‐visceral grafts, and those with missing exception applications for HCC were excluded. The population was randomly divided into development ( n = 15,282) and validation ( n = 15,283) cohorts. The primary outcome was 5‐year LT survival benefit, defined as the difference in survival with and without LT.
Results
C‐MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. The HCC‐Liver Transplant Survival Benefit model was defined as HCC‐LTSB = 0.65 × (C‐MELD 145 3.0 − 6) + 1.99 × (TBS − 2.25) + 0.68 × log2(AFP). Validation demonstrated strong performance (Pearson's r = 0.93; 95% CI: 0.93–0.94; R 2 = 0.87; C‐index = 0.91).
Conclusion
The HCC‐LTSB model accurately predicted the survival benefit provided by LT in candidates listed with unresectable HCC within UNOS criteria.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- J.C. Walter Jr. Transplant Center and Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA.
- Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Surgery, Georgetown University, Washington D.C., USA.
- School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID profiles: Isabel Neckermann, Michele Molinari
Cite
APA
Liu, H., Neckermann, I., Mial-Anthony, J., Elias, C., Abdullah, A., Sethi, V., Kaltenmeier, C., Rahman, A., Ashwat, E., Godwin, P., Sabin, S., Fokken, T., Han, S., Zhang, X., Dharmayan, S., Behari, J., Celaj, S., & Molinari, M. (2026). Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model. Clinical Transplantation, 40(3). https://doi.org/10.1111/ctr.70488
Vancouver
Liu H, Neckermann I, Mial-Anthony J, Elias C, Abdullah A, Sethi V, et al. Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model. Clinical Transplantation. 2026;40(3). doi:10.1111/ctr.70488
BibTeX
@article{Liu2026,
author = {Liu, Hao and Neckermann, Isabel and Mial-Anthony, Jason and Elias, Charbel and Abdullah, Abiha and Sethi, Vrishketan and Kaltenmeier, Christopher and Rahman, Amaan and Ashwat, Eishan and Godwin, Packiaraj and Sabin, Subedi and Fokken, Timothy and Han, Shwe and Zhang, Xingyu and Dharmayan, Stalin and Behari, Jaideep and Celaj, Stela and Molinari, Michele},
title = {Optimizing Liver Transplant Allocation for Hepatocellular Carcinoma: Development and Validation of a Survival Benefit‐Based Model},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {3},
doi = {10.1111/ctr.70488}
}
EUVIMED